Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: last trading week of July and closer to sector Q2 earnings’ releases

July 26, 2021 7:39am

While the sector traded down from last Monday’s, Thursday’s and Friday’s weakness

Pre-open indications: 6 SELLs: AGTC, CPSP, BLUE, EDIT, GBT, SAGE; 1 BUY: VSTM and -1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Dow futures are DOWN -0.41% (-143 points), S&P futures are DOWN -0.26% (-11 point) and NASDAQ futures are DOWN -0.14% (-21 points)

U.S. stock futures are down and falling in early pre-open trade on Monday after record closing highs last week, and one of the busiest weeks of earnings reports is on deck in the week ahead,

European stocks were down adjusting to global sentiment

Asia-Pacific stocks were mixed with Hong Kong’s Hang Seng index falling sharply along with mainland Chinese markets.

Data Docket: The Fed’s two-day policy meeting begins Tuesday. The Federal Open Market Committee and the Board of Governors are expected to issue a statement on the stance of monetary policy Wednesday. On Thursday the Commerce Department will report Q2 GDP data. the U.S. Department of Housing and Urban Development will release new home sales data and the Federal Reserve Bank of Dallas will release its monthly business activity index for manufacturing in Texas.

Henry’omics:

More ready to stumble than rumble …

All three of the major averages finished at record closing highs last week after markets tumbled.

Friday’s evening’s recap: “the cell and gene therapy sector flipped to the downside with low volume and percentage moves” … https://www.regmedinvestors.com/articles/12017

The Nasdaq closed UP +152.39 points (+1.04%);
The IBB closed up +0.88% and XBI closed down -1.14%
Sector volume was LOW with 0 of the 10-upside having higher than the 3-month average volume with very LOW volume of 4 of 23-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -0.49 points or -2.77% at 17.20
Friday’s percentage (%) of the 10-upside were +0.27% (FATE) to +1.90% (MDXG) while the 23-downside ranges from -0.66% (ATHX) to -27.88% (ADVM);

Last week to date 2 positive (Tuesday and Wednesday) and 3 negative (Monday, Thursday and Friday) closes

Q3/21: July, 5 positive, 1 holiday and 11 negative close

Q2/21:

June: 15 positive and 8 negative closes
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?

Biostage (BSTG) closed flat, Friday and Thursday with 200 shares traded after Wednesday’s +$0.01 with 200 shares traded, Tuesday’s flat at $1.70 with 49 shares traded and Monday’s +$0.01 to $1.71 with 307 shares traded.

Question#1: WHAT is the end game or play-book for this company, it has not done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?

Question#2: Is it “alleged that market manipulation” i.e., “promotional’ tactics highlight how this equity is traded on the over-the-counter market?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

The morning’s indications:

SELL:

Applied Genetic Technologies (AGTC) closed down -$0.07 to $3.74 and has a negative pre-open indication of-$0.114 or -3.74,

CRISPR Therapeutics (CRSP) closed down -$2.50 to $122.27 and has a negative pre-open indication of -$1.77 or -1.45%

bluebird bio (BLUE) closed down -$1.00 to $25.98 after Friday’s -$0.51 to $26.98 and has a negative -$0.24 or -0.92% pre-market indication.

Editas Medicine (EDIT) closed down -$2.17 to $40.84 after Friday’s -$1.08 and has a negative -$0.34 or -0.83% pre-market indication.

Global Blood Therapeutics (GBT) closed down -$0.75 to $28.69 and has a negative -$0.53 or -1.85% pre-market indication.

Sage Therapeutics (SAGE) closed down -$0.74 to $45.03 and has a negative -$2.03 or -4.51% pre-open indication.

BUY:

Verastem (VSTM) closed down -$0.17 to $3.31 and has a positive +$0.19 or +5.74% preopen indication.

The BOTTOM LINE: Volatility is still front-and-center in the sector … after reviewing the week beginning the 19^th through the 23^rd.

The cell and gene therapy sector is still confusing as sentiment rages and fades, momentum is burped and usurped as fundamentals seem ignored.

Q2 earnings LPS (loss-per-share) release date are soon to be divulged and not positively; yet another – Sage Therapeutics (SAGE) and Alnylam Pharmaceuticals (ALNY) release “earnings” on 8/3 followed by Vericel (VCEL), MiMedx (MDXG), AxoGen (AXGN) on 8/4, Brainstorm Cell Therapeutics (BCLI) on 8/5 and Athersys ATHX) on 8/9 – so far.

Risk is no doubt increasing as we head into the troublesome August and September months

My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.